| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514160500 | Tissue development affecting | 31 |
| 20100286052 | Novel use of antisecretory factor - The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease. | 11-11-2010 |
| 20100298226 | POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA - An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof. | 11-25-2010 |
| 20110034390 | PEPTIDES, COMPOSITIONS, AND USES THEREOF - Compositions for regenerating tissue and wound repair, among other applications, are described. | 02-10-2011 |
| 20110275572 | Nanocomposite Hyaluronic Acid-Clay Based Hydrogels - Hydrogels formed from hyaluronic acid, a nanoclay and gelatin-type A. The hyaluronic acid is preferably dissolved in a cell culture medium containing amino acids, salts, glucose, vitamins and an antibiotic to form a hyaluronic acid solution. The gelatin-type A has a weight/volume of from about 0.02% to 0.08%. The nanoclay is exfoliated in deionized water and preferably includes SiO | 11-10-2011 |
| 20120040907 | Method of Use of Bioactive Materials - A bioactive material is made using fibroin solutions and suspensions designed to support the constructions, repair, regeneration or augmentation of bone and other tissues of the body. The fibroin solutions, suspensions, and composites can be injected to fill cavities or to replace missing tissue. After injection, the materials can produce a scaffold capable of promoting tissue regeneration while degrading. The ability to inject the fibroin solutions, suspensions and composites can reduce the need for many types of surgical procedures that are used to replace or repair bone and other tissues. The fibroin solutions and suspensions are particularly useful for methods of tissue construction and/or repair. | 02-16-2012 |
| 20120165262 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS INVOLVING EPITHELIAL CELL APOPTOSIS - The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient. | 06-28-2012 |
| 20120238500 | REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO - The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue. | 09-20-2012 |
| 20120309685 | PURIFIED EMD PROTEIN COMPOSITION - Pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55 kDa, formulated in a suitable pharmaceutical carrier. The composition is depleted of proteins which have a molecular weight between 56 and 160 kDa and an iso-electric point between 3-10. The purified Enamel Matrix Derivative (EMD) proteins are depleted of proteinase inhibitors, such as α1-antichymotrypsin and/or Fetuin A. The composition is preferably used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma. | 12-06-2012 |
| 20120329719 | Methods of use of skin wound healing compositions - A wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain. The composition includes a pharmaceutical medium to carry the polypeptide compound, such as an aqueous solution, suspension, dispersion, salve, ointment, gel, cream, lotion, spray or paste. Additionally, a method of applying a wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain in a concentration of from about 1 μg/ml to about 100 μg/ml for a time sufficient to heal the wound is disclosed. | 12-27-2012 |
| 20130184217 | TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS - Provided herein are compositions and methods for the modulation of 'miR-214 for the treatment and/of prevention of fibrosis arid fibroproliferative conditions. | 07-18-2013 |
| 20130210735 | EMD FORMULATION COMPRISING PGA - Enamel Matrix Derivative (EMD) proteins and enamel matrix proteins are widely used in clinical dentistry because of their ability to promote regeneration of soft and hard tissues and to reduce inflammation and infections. The present invention relates to the surprising finding that a pharmaceutical, dental and/or cosmetic formulation, which comprises purified Enamel Matrix Derivative (EMD) proteins and/or enamel matrix proteins and sterilized Propylene Glycol Alginate (PGA), wherein the sterilized PGA is obtained from non-sterilized PGA having a weight average molecular weight (M | 08-15-2013 |
| 20140045759 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein. | 02-13-2014 |
| 20140206619 | PEPTIDE FOR INDUCING REGENERATION OF TISSUE AND USE THEREOF - (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. | 07-24-2014 |
| 20140235543 | METHODS FOR ISOLATING AND USING A SUBSET OF CD8 T-CELLS THAT ARE RESISTANT TO INHIBITORS - Methods for identifying a subset of CD8 T cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain CD8 T cells expresses elevated levels of Scin and/or Pla2g4a, with an elevated level indicative of proliferation of the identified CD8 T cells. Also disclosed are methods of diagnosing, monitoring and treating rheumatoid arthritis and transplant rejection, including determining and/or monitoring the expansion of a subset of CD8 T cells by measuring the level of expression of a biomarker in the population of the CD8 T cell subset. | 08-21-2014 |
| 20140303086 | ENDOTHELIUM PROTECTIVE MATERIALS AND METHODS OF USE - Apolipoprotein M forms a complex with sphingosine-1-phosphate (S1P) and is the carrier of S1P in high density lipoprotein particles and mediates its endothelial protective effect. Increasing the concentration of the apoM/S1P complex by administering it, either alone or in HDL particles, can prevent or treat diseases caused by endothelial cell injury, including inflammatory diseases, sepsis, atherosclerosis and acute lung injury, ischemic heart disease, stroke, vital organ failure after ischemic stress. | 10-09-2014 |
| 20140336124 | Compositions for Regenerating Defective or Absent Myocardium - Injectable collagen based graft compositions and grafts formed from the compositions for tissue regeneration. The compositions and grafts further include a glycosaminoglycan (GAG) to control matrix formation and remodeling. | 11-13-2014 |
| 20150315234 | MYOBLAST DIFFERENTIATION PROMOTER - A peptide selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof has a myoblast differentiation promoting effect superior to conventional arts. | 11-05-2015 |
| 20150320865 | HYBRID HYDROGEL SCAFFOLD COMPOSITIONS AND METHODS OF USE - The present invention includes new hybrid hydrogel scaffolds comprised of a polyoxyethylene-polyoxypropylene (block) copolymer (a “poloxamer”) and a self-assembling peptide, which maintain the mechanical and bioactive properties of its individual constituents (as compared to when the individual constituents are scaffolds or hydrogels by themselves). The hydrogels of the invention can include a combination of materials from different origins or with different properties that provides a hybrid material that meets the multiple needs of a scaffold for tissue engineering. | 11-12-2015 |
| 20150328288 | METHODS OF GENERATING AND USING PROCOLLAGEN - A method of promoting wound healing, treating fibrosis and/or promoting angiogenesis is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a procollagen, thereby promoting wound healing, treating fibrosis and/or promoting angiogenesis in the subject. | 11-19-2015 |
| 20150359848 | Methods and Related Kits for Treating and Regenerating Tooth Pulp and Periapical Tissues in a Mammal - In one embodiment, a method of regenerating tooth pulp in a mammal is provided. The method comprises removing at least a portion the existing tooth pulp of a mammal and adding amelogenin protein to the existing tooth pulp of the mammal to regenerate tooth pulp in a mammal. In another embodiment, a method of treating necrotic tooth pulp of a mammal is provided. The method comprises providing at least one necrotic tooth pulp of a mammal with an amelogenin protein. In yet another embodiment, a kit for regenerating tooth pulp in a mammal is provided. The kit comprises an adequate amount of amelogenin protein for regenerating tooth pulp in a mammal and instructions for applying the amelogenin protein to at least one tooth pulp of the mammal. | 12-17-2015 |
| 20160000858 | COMPOSITIONS AND METHODS FOR MITIGATING SKIN IRRITATION AND ENHANCING SKIN BARRIER FUNCTION - Methods and compositions for cell regeneration and decreased irritation of mammalian skin cells are provided, wherein the compositions include a synergistic combination of two or more oligopeptides. The compositions may advantageously be applied to mammalian skin to effect a regeneration of skin cells and to effect a reduction in inflammation and redness experienced by the skin. Skin cleansing and sanitizing compositions are provided that include at least one oligopeptide, wherein the compositions have reduced irritancy potential. | 01-07-2016 |
| 20160000862 | USE OF PEDF-DERIVED POLYPEPTIDES FOR PROMOTING MUSCLE OR TENDON REGENERATION OR ARTERIOGENESIS - A method for promoting muscle or tendon regeneration, and/or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9. | 01-07-2016 |
| 20160000865 | COMPOSITIONS AND METHODS RELATING TO INDUCTION OF INTESTINAL STEM CELL HOMEOGENESIS AND/OR REGENERATION - The present invention relates to compositions and methods for inducing intestinal stem cell homeogenesis and/or regeneration within intestinal tissue expressing Robo1 through administration of a Rspo1 agent and a Slit2 agent. Administration of such agents results in, for example, binding of the Rspo1 agent and Slit2 agent with Robo1, resulting in, for example, binding of the CC3 motif of Robo1 with LRP6, resulting in phosphorylation of LRP6, and ultimately, induction of intestinal stem cell homeogenesis and/or regeneration. In certain embodiments, such administration of a Rspo1 agent and a Slit2 agent is used to protect and/or prevent intestinal tissue damage resulting from exposure to an intestinal tissue damaging event (e.g., radiation). The agents and related compositions additionally find use in diagnostic and research settings. | 01-07-2016 |
| 20160030505 | COMPOSITIONS FOR PREVENTION OF ADHESIONS AND OTHER BARRIER APPLICATIONS - A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue. | 02-04-2016 |
| 20160052994 | MODIFIED LAMININ CONTAINING COLLAGEN BINDING MOLECULE AND USE THEREOF - A modified laminin characterized in that a laminin or a heterotrimeric laminin fragment has a collagen binding molecule conjugated to at least one site selected from the α chain N-terminus, the β chain N-terminus and the γ chain N-terminus, and an extracellular-matrix material comprising the modified laminin, and collagen and/or gelatin serve as an alternative to Matrigel and are useful as an extracellular-matrix material for the formation of a safe three-dimensional tissue structure for regenerative medicine in humans. | 02-25-2016 |
| 20160060600 | METHOD FOR INDUCING HEMOBLAST DIFFERENTIATION - The present invention relates to the in vitro production of erythrocytes/granulocytes and to the treatment of myelodysplastic syndrome using a method for inducing hemoblast differentiation. The present invention provides a media composition comprising gelsolin as an active ingredient for inducing the differentiation of hematopoietic precursor cells into erythrocytes/granulocytes, and a pharmaceutical composition comprising gelsolin as an active ingredient for treating myelodysplastic syndrome. Since the composition of the present invention improves the efficiency of differentiation of hematopoietic precursor cells into erythrocytes/granulocytes while maintaining a low rate of occurrence of cell dysplasia and having the effect of improving the enucleation rate and cell survivability, the present invention can be effectively used for producing erythrocytes/granulocytes in vitro and for treating myelodysplastic syndrome. | 03-03-2016 |
| 20160144044 | Carboxymethylcellulose-Peptide Conjugates and Methods for Using the Same - Provided are compositions for repairing an injured tissue. The composition includes carboxymethylcellulose conjugated to an extracellular matrix derived peptide, and a methylcellulose. Also provided are kits and methods for using the subject compositions. | 05-26-2016 |
| 20160200782 | FORMULATION OF MK2 INHIBITOR PEPTIDES | 07-14-2016 |
| 20160375100 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity. | 12-29-2016 |
| 20190142894 | PEPTIDE HAVING EFFECTS OF INCREASING TELOMERASE ACTIVITY AND EXTENDING TELOMERE, AND COMPOSITION CONTAINING SAME | 05-16-2019 |
| 20190142897 | COMPOSITION FOR IMPROVING MUSCULAR FUNCTION OR FOR ENHANCING EXERCISE PERFORMANCE COMPRISING VIGNA ANGULARIS VAR. ANGULARIS | 05-16-2019 |
